Drug
Onapristone clinical trials
Includes 1 study of Extended-release Onapristone.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
8 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 4
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 5
Memorial Sloan Kettering Cancer Center (2) · Context Therapeutics Inc. (2) · Thomas Jefferson University (1) · SOLTI Breast Cancer Research Group (1) · University of Wisconsin, Madison (1) · Arno Therapeutics (1)
Often tested with
Tested in the same studies.
Anastrozole (2) · Elacestrant (2) · Fulvestrant (1) · Letrozole (1) · Palbociclib (1)
Studies
Open first, then newest update. How each study uses onapristone is read from its arms, and is right about nine times in ten.
Testing it · 8
- Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast CancerTerminatedPhase 1/2Context Therapeutics Inc.NCT05618613Written as Onapristone
- Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial CancerCompletedPhase 2Thomas Jefferson UniversityNCT04719273Written as Extended-release Onapristone
- A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to ProgesteroneCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT03909152Written as Onapristone ER
- A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast CancerWithdrawnPhase 1/2Context Therapeutics Inc.NCT06938711Written as Onapristone
- Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)TerminatedPhase 2University of Wisconsin, MadisonNCT04738292Written as Onapristone
- A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast CancerWithdrawnPhase 1Memorial Sloan Kettering Cancer CenterNCT04872608Written as Onapristone ER
- Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast CancerCompletedEarly Phase 1SOLTI Breast Cancer Research GroupNCT04142892Written as Onapristone
- Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing CancersStatus unknownPhase 1/2Arno TherapeuticsNCT02052128Written as onapristone
Given in every arm · 1 — onapristone is usual care beside what is tested
Codes
What other systems call onapristone · ClinicalTrials.gg INT003337
- MeSH (NLM) C053238onapristoneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) H6H7G23O3NONAPRISTONEConfirmed FDA, NLM, Wikidata
- Wikidata Q27088181onapristoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170255OnapristoneOne source FDA
- DrugBank DB12637One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C053238 | onapristone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | H6H7G23O3N | ONAPRISTONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27088181 | onapristone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170255 | Onapristone | One source FDA |
| DrugBank | DB12637 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.